Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ECLIPSE trial of atogepant for acute migraine attacks
CTR20240519Phase 3Active
- Sponsor
- AbbVie Inc.
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of atogepant in migraine, sponsored by AbbVie Inc.. Started May 2024; status: active.
02
Drugs
atogepant
03
Conditions
migraine
Beyond the preview
Go deeper on CTR20240519.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240519.